Clinical Trial Update: Envarsus Neurotoxicity Burden in Liver Transplant Patients [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the neurotoxicity burden of Envarsus (tacrolimus extended-release) in liver transplant recipients; results posted in 2024-06-27.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Transplantation
• Neurotoxicity

Drugs mentioned

• Envarsus XR (Tacrolimus)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Neurotoxicity, Liver Transplant; Complications | Phase 4 | Status: COMPLETED | Results posted: 2024-06-27